Designation, development and access of orphan drugs.

Authors

  • Ana Dácil Marrero Capitán

DOI:

https://doi.org/10.24310/enbio.v14i178.17045

Keywords:

Rare diseases, designation, orphan drugs

Abstract

This article aims to sum up the most important ideas discussed during the online series of conferences about Designation, Development and Access to Orphan Drugs organized by the Spanish Centre of Network Research of Rare Diseases (CIBERER) the past 28th of October 2020, in which experts from different areas (institution, companies and research) talked about the designation process for orphan drugs, the great importance of this classification, and the advantages this implies for the researchers in terms of the study of new therapies and drug development, and for pharmaceutical companies in terms of economical protection.

Downloads

Download data is not yet available.

References

Información sobre Enfermedades Raras | FEDER. https://enfermedades-raras.org/index.php/

enfermedades-raras.

Julián Isla: El padre que quiere mejorar el diagnóstico de enfermedades raras con inteligencia artificial | Tecnología. EL PAÍS. https://elpais.com/tecnologia/2019/08/12/actualidad/1565610083_028572.html.

Orphanet: Anemia de Fanconi. https://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=ES&Expert=84.

What is FA? | Fanconi Anemia Research Fund. http://www.fanconi.org/explore/what-is-fa

Downloads

Published

2023-06-22

Dimensions

PlumX

Issue

Section

Artículos

How to Cite

Designation, development and access of orphan drugs. (2023). Encuentros En La Biología, 14(178), 7-10. https://doi.org/10.24310/enbio.v14i178.17045